Neuraxpharm Brings In Greek Olanzapine Brand
Strikes Deal With Local Firm Lyofin To Expand In Greece With Lazap Antipsychotic
CNS specialist Neuraxpharm has snapped up the Lazap olanzapine brand in Greece from local firm Lyofin, helping to further expand its presence in the Greek market following a recent acquisition.
You may also be interested in...
In a two-pronged push into Latin America, European CNS specialist Neuraxpharm has set up operations in Mexico and Brazil, with the latter bolstered by the acquisition of local player Libber Pharma.
Struggling antibiotic company will go privare under the agreement. Bayer will employ Acuitas's liquid nanoparticle technology in gene therapies developed by subsidiary Asklepios.
Ahead of the Global Generics & Biosimilars Awards, which are this year being held on Wednesday 25 October at the Hotel Porta Fira in Barcelona, we reveal our final shortlist of entrants across all 14 categories.